Gyre Therapeuticsの空売り状況は、投資家がGyre Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Gyre Therapeutics (NASDAQ:GYRE) 株価情報, 空売り情報

Gyre Therapeutics

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Gyre Therapeutics Inc

Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) could show the company's leadership in the cryptocurrency ecosystem with first-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Wednesday.</a>
Earnings Estimates: Analysts expect Coinbase to report first-quarter revenue of $2.13 billion, up from $1.64 billion in last year's first quarter, according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0507">from Benzinga Pro. </a>
The company beat analyst estimates for revenue in the last reported quarter, while beating estimates in eight of the last 10 quarters overall.
Analysts expect Coinbase to report first-quarter earnings per share of $2.12, up from $1.65 in last year's first quarter. The company has beaten analyst estimates for earnings per share in eight straight quarters and eight of the last 10 quarters overall.
Read Also:<a href="https://www.benzinga.com/25/05/45244364/coinbase-spikes-in-after-hours-trading-after-partnership-with-lol-valorant-developer-riot-games"> Coinbase Stock Trades Higher After-Hours Amid Partnership With League Of Legends, Valorant Developer Riot Games</a>
What Analysts Are Saying: Rosenblatt analyst Chris Brendler recently warned that "crypto winter" could be underway and it <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44869664/coinbase-global-goes-from-boom-to-bust-amid-crypto-winter-analyst-trims-q1-estimates">could hurt momentum</a> for Coinbase stock.
The analyst said sentiment on crypto has reversed with "sharply rising macro concerns."
Brendler reiterated a Buy rating on the stock while lowering the price target from $305 to $290.
The analyst said Coinbase's trading volumes in March were likely lower than expected. Brendler sees a rebound in crypto-related trading activity in the second half of 2025.
"In our view, legislative clarity will accelerate blockchain technology adoption and COIN will be a primary beneficiary," Brendler said.
Goldman Sachs analyst James Yaro<a href="https://www.benzinga.com/government/regulations/25/03/44421767/coinbase-analyst-cautiously-optimistic-on-stock-with-balanced-riskreward-says-regulatory-e"> sees a balanced risk/reward </a>for Coinbase heading into the earnings report. The analyst took over coverage of Coinbase at Goldman Sachs after the stock was previously covered by Will Nance.
Yaro gave Coinbase a Neutral rating and a $195 price target.
With pure-play exposure to the cryptocurrency sector, Yaro sees long-term growth for Coinbase as the crypto ecosystem expands.
&#8220;We are cautiously optimistic on COIN, but see a balance of upside and downside risks,&#8221; Yaro said.
Yaro highlights a positive regulatory environment for crypto that could support Coinbase&#8217;s growth, but also be a negative.
&#8220;Longer-term, regulatory reform could increase the crypto TAM, but also bring in competitors from across financial services. Competition could pressure COIN&#8217;s market share and pricing over time.&#8221;
Here are other recent <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">analyst ratings on Coinbase</a> and their price targets:
<ul>
<li>Citigroup: Maintained Buy rating, lowered price target from $350 to $270</li>
<li>JPMorgan: Maintained Neutral rating, lowered price target from $344 to $276</li>
<li>Benchmark: Initiated with Buy rating, $252 price target</li>
</ul>
Key Items to Watch: Analysts and investors will be looking at many items in Coinbase's earnings report with the price of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) trading strong in January before falling in March.
Transaction revenue was up 172% quarter-over-quarter in the fourth quarter. This could be a key item to show whether Coinbase continues its leadership in the cryptocurrency ecosystem and also if traders were active in the first quarter with Donald Trump inaugurated and high volatility during the quarter.
Subscription and services has been a bright spot for Coinbase in recent quarters, bringing the company high-margin recurring revenue. Subscription and services revenue of $641 million in the fourth quarter was up 15% quarter-over-quarter and came in ahead of company guidance. The company<a href="https://www.benzinga.com/25/02/43713994/coinbase-q4-earnings-highlights-revenue-beat-consumer-trading-volume-940-billion-company-welcomes-dawn-of-a-new-era-for-crypto"> is guiding for </a>first-quarter subscription and services revenue in a range of $685 million to $765 million.
Bitcoin made up 27% of both trading volume and transaction revenue in the fourth quarter. This was down from 37% and 35% respectively, in the third quarter. The new quarterly results will show if Bitcoin regained its dominance or saw lower activity due to other cryptocurrencies.
XRP Token (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) could be another item to watch after making up 14% of transaction revenue in the fourth quarter and seeing strong demand from Coinbase users.
COIN Price Action: Coinbase stock is down 0.7% to $195.47 on Wednesday versus a 52-week trading range of $142.58 to $349.75. Coinbase stock is down 21.4% year-to-date in 2025 and down 8.9% over the last year.
The drop in Coinbase's stock price comes with Bitcoin up 3.1% year-to-date and up 54.5% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43591727/coinbase-ceo-brian-armstrong-says-bitcoin-adoption-to-reach-billions-by-2030">Coinbase CEO Brian Armstrong Says Bitcoin Adoption To Reach &#8216;Billions&#8217; By 2030</a></li>
</ul>
Image: Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Price Target

Previews

Reiteration

Analyst Ratings

Trading Ideas

$BTC

$XRP

COIN

Coinbase Q1 Earnings Preview: Trump Inauguration, Bitcoin Surge And More Items To Watch

Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) released its <a target="_blank" href="https://www.benzinga.com/general/gaming/25/05/45238060/electronic-arts-stock-climbs-after-better-than-expected-q4-report" rel="noreferrer noopener">fourth-quarter results</a> after Tuesday&#8217;s closing bell.&nbsp;
Wall Street analysts rerated the stock after the report.
Wedbush analyst Michael Pachter reiterated Electronic Arts with an Outperform and raised the <a target="_blank" href="https://www.benzinga.com/quote/EA/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$179&nbsp;to&nbsp;$210</a>.
JP Morgan analyst Cory A Carpenter maintained Electronic Arts with a Neutral and raised the price target from&nbsp;$135&nbsp;to&nbsp;$160.
Also Read: <a href="https://www.benzinga.com/25/03/44524101/take-two-and-roblox-set-for-big-2025-gains-as-gta-vi-mobile-growth-and-ads-drive-momentum-analyst" target="_blank" rel="noreferrer noopener">JP Morgan&#8217;s Top Video Game Stocks Of 2025</a>
Wedbush: Electronic Arts reported net bookings of $1.799 billion compared with Pachter&#8217;s estimate of $1.594 billion, consensus of $1.550 billion, and guidance of $1.444 billion-1.594 billion. Revenues exceeded expectations, driven by a rebound in EA SPORTS FC, the successful launch of Split Fiction, double-digit net bookings growth in The Sims, and continued strength in American Football titles. 
Adjusted EPS was $1.58, compared with Pachter&#8217;s estimate of $1.21, consensus of $1.10, and guidance of $0.76– 1.17. Fiscal 2026 guidance for net bookings of $7.600 billion-8.000 billion and adjusted EPS of $7.60-8.40, compared with Pachter&#8217;s prior estimates of $7.830 billion and $8.38 and previous consensus of $7.900 billion and $6.93. 
First-quarter 2026 guidance is for net bookings of $1.175 billion-1.275 billion and EPS of $(0.05)-0.15, compared with Pachter&#8217;s prior estimates of $1.250 billion and $0.51, and prior consensus of $1.264 billion and $0.23. First-quarter guidance assumes seasonally lower revenue, a five-point drag from Apex Legends, and a two-point drag from the catalog. Excluding Apex Legends, EA expects low single-digit live services growth in the period.
Pachter noted that the launch of Battlefwill likely result in sales of 7 million-15 million units for the year and expects Skate to add 3 million-5 million units more. At the low end, these titles should contribute $500 million of year-over-year growth; at the high end, they should contribute $1 billion. 
Perhaps more importantly, Electronic Arts&#8217; guidance contemplates that retail game prices will remain $70 for Xbox Series and PS5 releases. Electronic Arts noted it is highly likely that the company can raise prices for ALL of its new releases by $10 at retail, allowing it to capture $350 million of bookings growth in fiscal 2026 with only modest performance from its latest titles.
Pachter projected first-quarter revenue of $1.28 billion and EPS of $0.15.
JP Morgan: Three months ago, investors debated if the FC slowdown was temporary or structural, Dragon Age disappointed, and a Battlefield release in fiscal 2026 was uncertain due to GTA VI. A lot has changed in three months. FC proved to be a temporary &#8220;ebb,&#8221; the delay of GTA VI opened a window for Battlefield to launch in fiscal 2026, and Split Fiction nearly doubled expectations, according to Carpenter.
Carpenter listed his takeaways from management calls. The outlook does not include game price increases, but the analyst would not interpret them as off the table. Battlefield unit assumptions are prudent, given that the game has been out of the market for about four years. 
The analyst noted Electronic Arts could achieve the low end of its fiscal 2027 margin framework a year early in a Battlefield &#8220;blue sky&#8221; scenario. The fiscal first-quarter outlook reflects FC trends consistent with recent weeks, which could prove conservative given the significant upcoming events in the quarter.
Battlefield will have live services tied to it, but management has yet to disclose the timing. Carpenter noted the outlook reflects Battlefield live services assumptions that are even more conservative than unit assumptions.
Apex 2.0 release timing will likely be further out so as not to conflict with Battlefield.
Catalog is a bigger headwind than Apex for the fiscal year, but Apex is a bigger headwind in the fiscal first quarter.
Carpenter did not anticipate any material change to the dividend.
He projected first-quarter revenue of $1.6 billion and adjusted EPS of $0.04.
Price Action: EA stock is up 1% at $156.08 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45252365/fiverr-beats-q1-on-strong-buyer-spend-and-ai-push-lifts-2025-revenue-outlook" target="_blank" rel="noreferrer noopener">Fiverr Beats Q1 Estimates On Strong Buyer Spend, AI Push, Lifts 2025 Revenue Outlook</a></li>
</ul>
Photo: Shutterstock

News

EA's Strong Quarter Turns Heads On Wall Street As Analysts Reassess The Road Ahead

Major cryptocurrencies are trading slightly higher following the Federal Reserve keeping interest rates unchanged and China's liquidity boost to stimulate its economy.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$96,034.89</td>
<td>+1%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$1,792.80</td>
<td>+0.2%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$145.55</td>
<td>+0.4%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.10</td>
<td>-1.6%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1700</td>
<td>+0.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001262</td>
<td>+0.3%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume decreasing by 9.4% and daily active addresses growing by 3.2%. Transactions greater than $100,000 are down from 9,843 to 9,668 in a single day. Exchanges netflows are down by 140.2%.</li>
<li>Coinglass data reports 102,179 traders were liquidated in the past 24 hours for $239.75 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/25/05/45260729/ethereums-pectra-upgrade-goes-live-reshapes-wallet-logic-and-raises-security-and-bandwidth-concerns">Ethereum&#8217;s Pectra Upgrade Goes Live: Here&#8217;s What You Need To Know</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45257429/michael-saylor-calls-bitcoin-the-corporate-survival-strategy-for-96-of-companies">Michael Saylor Calls Bitcoin The &#8216;Corporate Survival Strategy&#8217; For 96% of Companies</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45248407/rabbitx-founder-eyes-real-world-assets-and-liquidity-tokenization-as-the-future-of-perpetual-trading">RabbitX Founder Eyes Real-World Assets And Liquidity Tokenization As The Future Of Perpetual Trading</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45262012/treasury-sec-scott-bessent-us-should-be-the-premier-destination-for-digital-assets">Treasury Sec Scott Bessent: US Should Be The &#8216;Premier Destination For Digital Assets&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45253032/anthony-scaramucci-gives-donald-trump-b-or-a-on-crypto-but-warns-presidential-meme-coin-defi-project-risk-derailing-policy-progress">Anthony Scaramucci Gives Donald Trump &#8216;B+ Or A-&#8216; On Crypto But Warns Presidential Meme Coin, DeFi Project Risk Derailing Policy Progress</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45248184/bitcoin-is-no-longer-just-digital-gold-native-staking-yield-are-redefining-its-role-says-core-dao">Bitcoin Is No Longer Just Digital Gold — Native Staking, Yield Are Redefining Its Role, Says Core DAO</a></li>
<li><a href="https://www.benzinga.com/25/05/45245329/strike-launches-new-service-allowing-users-to-borrow-up-to-2-million-backed-by-bitcoin">Have Bitcoin? Need Cash? Strike Launches New Product Allowing Users To Borrow Up To $2 Million</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>EOS (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eos/usd">EOS</a>)</td>
<td>&nbsp;$0.7813</td>
<td>+13.8%</td>
</tr>
<tr>
<td>Stacks (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/stx/usd">STX</a>)</td>
<td>&nbsp;$0.8459</td>
<td>+10.2%</td>
</tr>
<tr>
<td>Zcash (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/zec/usd">ZEC</a>)</td>
<td>&nbsp;$39.78</td>
<td>+9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader McKenna <a href="https://x.com/Crypto_McKenna/status/1920190448364388552">emphasized</a> that Bitcoin's explosive rise from $15,000 post-FTX to $110,000 has occurred despite interest rates holding steady at 4.25%–4.5%, underscoring that the rally is not rate-driven. 
Instead, he credits the move to structural adoption, particularly by institutions, and Bitcoin&#8217;s growing role as a non-sovereign store of value and hedge against capital controls. 
The parabolic trend, he notes, reflects a global shift in perception rather than temporary macro factors.
Inmortal echoed this long-term bullishness, pointing out that after long stretches of vertical accumulation, there's usually a "banger move" and we may still see more upside before a major deviation.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Even in vertical accumulations we get this banger at some point. We may have more upside before we have a deviation, but when it comes, I&#39;ll go big.<a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> <a href="https://t.co/3tGmUp5kMD">pic.twitter.com/3tGmUp5kMD</a>
&mdash; Inmortal (@inmortalcrypto) <a href="https://twitter.com/inmortalcrypto/status/1920192912224366700?ref_src=twsrc%5Etfw">May 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
ShardiB2 kept it simple: "Bitcoin daily looks fine — Above blue line, green dots," signaling a continued uptrend.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> daily looks fine Above blue line, green dots <a href="https://t.co/TtEi2sFvEI">pic.twitter.com/TtEi2sFvEI</a>
&mdash; Don&#39;t follow Shardi B if you hate Money (@ShardiB2) <a href="https://twitter.com/ShardiB2/status/1920192256545374307?ref_src=twsrc%5Etfw">May 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Crypto Seth <a href="https://x.com/seth_fin/status/1920176983587131838">advised</a> traders to stay focused amid expected short-term volatility following Jerome Powell's speech. "This BTC cycle isn't done, we've still got more to go," he asserted, urging market participants to keep their eyes on the bigger picture.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45259065/bitcoin-hovers-around-97000-but-a-correction-may-be-around-the-corner-traders-warn">Bitcoin Hovers Around $97,000, But A Correction May Be Around The Corner, Traders Warn</a></li>
</ul>
Image: Shutterstock

$DOGE

$EOS

$ETH

$SHIB

$SOL

$STX

$ZEC

Bitcoin, Ethereum, XRP, Dogecoin Continue Trading Sideways As Fed Keeps Interest Rates Unchanged

WIIM

ATOM

Atomera shares are trading higher. The company reported Q1 financial results.

Datadog Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) Tuesday announced <a href="https://www.benzinga.com/news/earnings/25/05/45221686/datadog-tops-q1-estimates-raises-revenue-outlook-flags-margin-pressure">upbeat first-quarter revenues</a>.
Here are some key analyst takeaways.
<ul>
<li>Wedbush <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00ad4e3513fb0001f03cfd/daniel-ives">analyst Daniel Ives</a> maintained an Outperform rating, while reducing the price target from $155 to $140.</li>
<li>Needham <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/601a8839a6fe6f00010c6966/mike-cikos">analyst Mike Cikos</a> reaffirmed a Buy rating, while cutting the price target from $160 to $130.</li>
<li>Cantor Fitzgerald <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61e7dac6ecb07f0001d8956b/thomas-blakey">analyst Thomas Blakey</a> reiterated an Overweight rating and price target of $134.</li>
<li>Goldman Sachs <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c6ab8db85e9300015f1ae0/kash-rangan">analyst Kash Rangan</a> maintained a Buy rating and price target of $127.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Wedbush: Datadog reported its first-quarter results with "beats across the board," Ives said in a note. Bookings were strong during the quarter, with RPO (remaining performance obligations) coming in at $2.31 billion, up 33% year-on-year.
Management raised their 2025 revenue guidance to a range of $3.215 billion to $3.235 billion, above the Street's $3.20 billion estimate, as the company "maintains a solid pipeline across its entire customer base for cloud migration and digital transformation projects," Ives stated. 
However, the operating margin guidance of $625 million to $645 million came in below the Street's $680.3 million estimate, Ives noted. The company is ramping up hiring plans while looking for &#8220;cost efficiencies in its cloud costs.&#8221;
Needham: Datadog reported solid quarterly results and guided to second-quarter revenue above consensus, Cikos said. 
Datadog's sales representative headcount grew by more than 25% year-on-year, "with a greater emphasis on the Enterprise segment and International," he added.
Management indicated that AI-Natives had risen to 8.5% of ARR (annual recurring revenues), the analyst stated. However, the company lowered its 2025 operating profit guidance by $30 million "to account for $15 Million in OpEx tied to currency and $10 Million from the Eppo and Metaplane acquisitions," he further wrote.
Cantor Fitzgerald: Datadog reported strong first-quarter results. Its AI native cohort drove momentum. Plus, record levels of new logo bookings grew 70% year-over-year, Blakey wrote in a note. The company generated total revenue growth of 24.6%, higher than consensus expectations.
Management raised their full-year revenue guidance by $40 million, despite the first-quarter beat being $23 million. "We continue to believe Datadog is a unique asset in software, with market leadership in a strategically growing market centered on cloud-focused observabiltiy including AI," Blakey added.
Goldman Sachs: Datadog's NRR trended in the high 110s for a second straight quarter, Rangan said. The stock came under pressure due to the company's gross margins coming in below consensus and the second consecutive quarter of weaker-than-expected operating margin guidance for the full year.
"We view AI Revenue driven largely by inference as a positive, given this revenue stream's sustainability should ease investors' concerns around topline volatility," Rangan wrote.
DDOG Price Action: At the time of publication on Wednesday, shares of Datadog had declined by 0.89% to $105.12.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45045012/sabre-divests-hospitality-arm-tpg-plans-debt-reductioncore-platform-focus">These Analysts Revise Their Forecasts On Datadog After Q1 Results</a> </li>
</ul>
Image: Shutterstock

Earnings Beats

DDOG

Datadog Lifts Revenue Outlook, Analysts Still Bark About Margins

SNCR

Synchronoss Technologies shares are trading lower after the company reported worse-than-expected Q1 financial results and issued FY25 sales guidance below estimates.

Macro Notification

General

AVGO

INTC

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Shares of chip stocks are trading higher following a report indicating President Trump will rescind global chip curbs.

ACET

Adicet Bio shares are tracing lower. The company reported Q1 financial results.

<a href="https://www.bloomberg.com/news/articles/2025-05-07/trump-to-rescind-global-chip-curbs-amid-ai-restrictions-debate" title="https://www.bloomberg.com/news/articles/2025-05-07/trump-to-rescind-global-chip-curbs-amid-ai-restrictions-debate">https://www.bloomberg.com/news/articles/2025-05-07/trump-to-rescind-global-chip-curbs-amid-ai-restrictions-debate</a>

Macro Economic Events

Global

Economics

ASML

LRCX

LSCC

NXPI

RMBS

'Trump To Rescind Global Chip Curbs Amid AI Restrictions Debate' - Bloomberg News

<a href="https://fortune.com/2025/05/07/green-dot-walmart-apple-prepaid-debit-cards-private-equity-citigroup-fintech-banks/" title="https://fortune.com/2025/05/07/green-dot-walmart-apple-prepaid-debit-cards-private-equity-citigroup-fintech-banks/">https://fortune.com/2025/05/07/green-dot-walmart-apple-prepaid-debit-cards-private-equity-citigroup-fintech-banks/</a>

GDOT

'Fintech Giant Green Dot Attracts Private Equity Interest Despite Sluggish Deal Climate' - Fortune

Doubleline Capital's Gundlach Says As The Economy Weakens, Long Term Interest Rates Could Very Well Be Going Above; We're In A Risk-Off Market On Intermediate Term Basis; I Do Think The Fed Will Probably Cut Rates By Year End

On May 1, 2025, Rani Therapeutics Holdings, Inc. ("Company") received a letter ("Notice") from the Nasdaq Stock Exchange LLC ("Nasdaq"), addressing a compliance deficiency under the Nasdaq Listing Rules. The letter notified of the deficiency with regard to Rule 5450(b)(2)(A), which requires a company whose securities are listed on The Nasdaq Global Market under the "Market Value Standard" to maintain a minimum Market Value of Listed Securities (an "MVLS") of $50,000,000. The deficiency was caused by the Company's MVLS having been below the minimum level for the prior 30 consecutive business days.

RANI

Rani Therapeutics Says On May 1, 2025 It Received A Letter Of Non-Complaisance From Nasdaq

RIGL

RIGL stock has given up its prior gain. Rigel Pharmaceuticals shares were trading higher after the company reported Q1 financial results and beat its EPS and sales estimates.

Movers

NTCL

NETCLASS TECHNOLOGY Shares Halted For Volatility

At their meeting held today, the Board of Directors of Chesapeake Utilities Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) voted to increase the quarterly cash dividend on the Company's common stock from $0.64 per share to $0.685 per share. The Board's action raises the 2025 annualized dividend by $0.18 from $2.56 to $2.74 per share, a 7 percent increase. The $0.685 per share dividend will be payable July 7, 2025 to all shareholders of record at the close of business on June 16, 2025.

Dividends

Chesapeake Utilities Increases Quarterly Cash Dividend From $0.64 To $0.685/Shr; Ups Annualized Dividend By 7% From $2.56 To $2.74/Shr

IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) held its Think 2025 event in <a href="https://www.benzinga.com/25/05/45259042/ibm-thinks-big-ai-delivers-bigger-why-bulls-are-charging-toward-300">Boston on Tuesday. </a> 
The key takeaway from the event is the company's portfolio of software products and services being "integral to large enterprise customers as they leverage AI across their organizations," according to Goldman Sachs.
The IBM Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5805f8a2846faa000106ab15/james-schneider">Analyst James Schneider</a> maintained a Buy rating and price target of $270.
The IBM Thesis: The company launched LinuxONE 5, which enables 450 billion secure AI inference operations per day, Schneider said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The company also introduced an upgraded watsonx.data, which taps unstructured data to increase accuracy of AI agents, he added.
"CEO Arvind Krishna noted that AI is shifting from experimentation to delivering measurable business value, with an emphasis on productivity and cost efficiency," the analyst wrote.
IBM projected that AI agents could power 30% of the one billion new applications by 2028, he further stated.
By applying its AI solutions internally, the company can "support ongoing margin expansion and FCF growth &#8211; even as it executes on M&amp;A," Schneider said.
IBM Price Action: Shares of IBM were up 1.1% to $252.02 at the time of publication on Wednesday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45218573/ibms-ai-watsonx-integrates-with-oracle-cloud-to-boost-enterprise-productivity">IBM AI Watsonx Integrates With Oracle Cloud To Boost Enterprise Productivity</a></li>
</ul>
Photo: Shutterstock

Long Ideas

IBM's AI Push Takes Center Stage At Think 2025, Goldman Sees Path To Margin Growth

XChange TEC.INC shares are trading lower after the company announced plans to change its ADS ratio from 1-to-120 to 1-to-2400.

Hedge Funds

Doubleline Capital's Gundlach Says We're In A Risk-off Market On Intermediate Term Basis

GLBZ

Glen Burnie shares are trading lower after the company reported a year-over-year decrease in Q1 sales results.

Chardan Research initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) on Wednesday, citing the potential of its <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">epilepsy franchise</a>.
Analyst Rudy Li writes, &#8220;Epilepsy remains one of our favorite markets in the CNS space, and we view Praxis as a diversified play in epilepsy, with a portfolio of products leveraging validated drug targets.&#8221;
Praxis had $472.0 million in cash, cash equivalents, and marketable securities as of March 31, which is expected to fund operations into 2028.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40691948/praxis-precision-medicines-touts-encouraging-data-for-mid-stage-epilepsy-drug" rel="noreferrer noopener">Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug</a>
In March, Praxis released interim data from Study 1 of the Essential3 program of ulixacaltamide&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44087912/analyst-cut-price-targets-for-praxis-precision-after-trial-setback-for-essential-tremor-candidate" rel="noreferrer noopener">in essential tremor (ET)</a>.
The Independent Data Monitoring Committee recommended stopping the study for futility. The results are unlikely to meet the primary efficacy endpoint.
<ul>
<li>&#8220;While we believe that the Phase 3 studies are unlikely to work (and we have not modeled for), we believe it is also possible that the FDA could provide regulatory flexibility given the unmet need for ET, which could provide additional upside to the story,&#8221; analyst Li writes.</li>
<li>In its first-quarter earnings release, the company said it decided to complete the studies and will share topline results in the third quarter of 2025. After reviewing the results of both studies, Praxis will decide if there is sufficient evidence to <a href="https://www.benzinga.com/pressreleases/25/05/g45164110/praxis-precision-medicines-provides-corporate-update-and-reports-first-quarter-2025-financial-resu" target="_blank" rel="noreferrer noopener">support an NDA filing</a>.</li>
</ul>
The analyst initiated with a Buy rating and a<a target="_blank" href="https://www.benzinga.com/quote/PRAX/analyst-ratings" rel="noreferrer noopener"> price forecast of $80</a>.
Chardan is optimistic <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37941441/why-praxis-precision-medicines-stock-is-trading-higher-tuesday" rel="noreferrer noopener">about vormatrigine&#8217;s (formerly PRAX-628) potential</a> in treating major types of epilepsy, especially focal onset seizures and generalized epilepsy, with possible peak sales over $1 billion.
<ul>
<li>As a next-generation sodium channel modulator, vormatrigine stands out from older drugs and current standard treatments because of its strong potency and targeted action, which could lead to better effectiveness and fewer side effects.</li>
<li>Early trials showed it has a wide safety margin, and a separate study showed high response rates in patients with light-triggered seizures.</li>
</ul>
Talking about Praxis&#8217;s elsunersen, an antisense product, Chardan writes that the product could become the first disease-modifying therapy for the treatment of SCN2A Gain-of-Function (GoF) DEE, which is a rare indication (~2K patients)
Price Action: PRAX stock is up 7.31% at $37.74 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45257204/chinese-biotech-beigene-stock-falls-despite-strong-brukinsa-sales-and-earnings-beat" target="_blank" rel="noreferrer noopener">Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Initiation

PRAX

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

Earnings

Press Releases

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Events

Sidoti Events, LLC's Virtual August Micro-Cap Conference

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Management

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

Comments

Gyre Therapeutics

空売り

Gyre Therapeutics (NASDAQ:GYRE) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル